肝硬化肌少症的治疗策略及研究方向

摘要/Abstract

摘要： 肌少症是肝硬化患者常见的骨骼肌异常,它的发生发展与营养不良、高氨血症、激素水平异常、门静脉高压等多种因素有关,因其早期治疗可改善肝硬化患者的预后而受到国内外学者的广泛关注。现有的研究结果初步证实,营养支持疗法、降氨治疗、调节异常的激素水平和降低门脉高压等措施对肝硬化肌少症的改善有效,但由于研究设计方法学局限、混杂因素干扰、结局指标评估方法的不一致性等原因,给现有的研究结果解读带来了挑战。本文总结了肝硬化肌少症的治疗措施,归纳了现有的研究局限性,旨在为未来的研究设计提供方向。

关键词: 肝硬化, 肌少症, 支链氨基酸, 降氨治疗, 胰岛素样生长因子-1

陶子文, 杨长青. 肝硬化肌少症的治疗策略及研究方向[J]. 肝脏, 2023, 28(6): 643-645.

参考文献

[1] Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol (1985),2003,95:1717-27.
[2] Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol,2019,54:845-859.
[3] Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One,2017,12:e0186990.
[4] Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol,2022,76:588-599.
[5] Ebadi M, Burra P, Zanetto A, et al. Current treatment strategies and future possibilities for sarcopenia in cirrhosis. J Hepatol,2023,78:889-892.
[6] Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,74:1611-1644.
[7] Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology,2008,48:557-566.
[8] Ismaiel A, Bucsa C, Farcas A, et al. Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis. Front Nutr, 2022,9:749969.
[9] Konstantis G, Pourzitaki C, Chourdakis M, et al. Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis. Clin Nutr 2022;41:1171-1190.
[10] Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology,2015,61:2018-2029.
[11] Lattanzi B, Bruni A, Di Cola S, et al. The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. Nutrients,2021,13(7):2296.
[12] Hiraoka A, Michitaka K, Kiguchi D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol,2017,29:1416-1423.
[13] Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol,2018,53:427-437.
[14] Uojima H, Sakurai S, Hidaka H, et al. Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. Eur J Gastroenterol Hepatol,2017,29:1402-1407.
[15] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology,2017,65:2045-2058.
[16] Murata K, Kaji K, Nishimura N, et al. Rifaximin enhances the L?carnitine?mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut liver muscle axis. Int J Mol Med,2022,50(2):101.
[17] Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. Hepatol Commun, 2019,3:348-355.
[18] Ohashi K, Ishikawa T, Hoshii A, et al. Effect of levocarnitine administration in patients with chronic liver disease. Exp Ther Med,2020,20:94.
[19] Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab,2008,33:997-1006.
[20] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol, 2016,65:906-913.
[21] Saeki C, Kanai T, Nakano M, et al. Low Serum Branched-Chain Amino Acid and Insulin-Like Growth Factor-1 Levels Are Associated with Sarcopenia and Slow Gait Speed in Patients with Liver Cirrhosis. J Clin Med,2020,9(10):3239.
[22] Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol,2005,43:630-636.
[23] Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest,2005,128:1187-1193.
[24] Feike Y, Zhijie L, Wei C. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton),2021,4:221-233.
[25] Tsien C, Shah SN, McCullough AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol,2013,25:85-93.
[26] Gioia S, Merli M, Nardelli S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int,2019,39:871-877.
[27] Hirooka M, Koizumi Y, Tanaka T, et al. Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis. Hepatol Commun, 2020,4:1812-1823.
[28] Ebadi M, Bhanji RA, Dunichand-Hoedl AR, et al. Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis. Nutrients,2020,12(11):3463.